Replies to post #111391 on Biotech Values

[DewDiligence]

“Teva will presumably try to turn the low-volume formulation into the centerpiece of its franchise defense.”

Basically, is that what's going on here?

That’s what was going on here, but the FDA just shot a hole in Teva’s plan.

Teva’s fallback position on defending the Copaxone franchise will now pass to the thrice-weekly 40mg formulation, which is being tested in a trial called GALA that is expected to report top-line data in late 2012 and the complete dataset in mid 2014 (#msg-57549803).